Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study

Rok, strany: 2005, 497 - 501

The aim of this study was to determine efficacy and toxicity of TIP combination (paclitaxel, ifosfamid, cisplatin) as first salvage treatment in patients with relapsed germ cell tumours (GCTs). Excellent results were achieved from TIP combination with a dose 250 mg/m2 of paclitaxel [5]. Our hypothesis was that comparable efficacy with less toxicity could be achieved even with a lower dose of 175 mg/m2 paclitaxel in TIP. In 17 consecutive patients with failed standard 1st line treatment, we used four to six courses of paclitaxel 175mg/m2 on day 1 and ifosfamide 1200 mg/m2 plus cisplatin 20 mg/m2, both on day 1 through 5, every 3 weeks. Eleven patients achieved favorable response (65%; 95% confidence interval, 42 to 87%) with 7 complete responses (41%). Estimated 2-year disease free survival is 47% (95% CI, 23-71%). Treatment combination was well tolerated and myelosupression was major toxicity. Granulocytopenia Gr3-4 was observed in 8% and febrile neutropenia in 7% of the courses. No case of severe neurotoxicity or treatment-related death was observed. In our study, TIP combination had good toxicity profile. The results however, did not show expected treatment efficacy and we raise the idea of paclitaxel dosage relevance in TIP.

ISO 690:

Mardiak, J., Šálek, T., Syčová-Milá, Z., Obertova, J., Hlavata, Z., Mego, M., Rečková, M., Koza, I. 2005. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study. In NEOPLASMA, vol. 52, no.6, pp. 497-501. 0028-2685.

APA:

Mardiak, J., Šálek, T., Syčová-Milá, Z., Obertova, J., Hlavata, Z., Mego, M., Rečková, M., Koza, I. (2005). Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study. NEOPLASMA, 52(6), 497-501. 0028-2685.